Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages

References

• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998; 339: 1506–1514.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswold meeting. J Clin Oncol 1989; 7: 1630–1636.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59.
   PubMed Web of Science ®Google Scholar
• Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010; 7: 301–302.
   PubMed Web of Science ®Google Scholar
• Horning JS. Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program. 2007:197--203. [Review].
   Google Scholar
• Schechter GP, Wahl LM, Oppenheim JJ. Suppressor monocytes in human disease: a review. Adv Exp Med Biol 1979; 121B: 283–298.
   PubMedGoogle Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl JMed 2010; 362: 875–885.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Lymphoma/leukemia molecular profiling project. Stromal gene signatures in large-B-cell lymphoma. N Engl J Med 2008; 359: 2313–2323.
   PubMed Web of Science ®Google Scholar
• Sehn L. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:295–302. [Review].
   Google Scholar
• Canioni D, Salles G, Mounier N, et al. High numbers of tumor associated macrophages have adverse prognostic value that can be circumvented by Rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440–446.
   PubMed Web of Science ®Google Scholar
• Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma. Onkologie 2012; 35: 733–739.
   PubMedGoogle Scholar
• Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011; 52: 1913–1919.
   PubMed Web of Science ®Google Scholar
• Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin’s lymphoma. Haematologica 2012; 97: 1080–1084.
   PubMed Web of Science ®Google Scholar
• Li ZM, Huang JJ, Xia Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Colgan J, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 2012; 97: 262–269.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, André M, et al. ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii70–iii75.
   PubMed Web of Science ®Google Scholar
• Specht L. Tumour burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer 1992; 28A: 1982–1985.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference leukocyte differential count (proportional) and evaluation of instrument methods. Approved standard. CLSI document H20-A2. Wayne PA: CLSI; 2007.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hematopoetic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the 14th International Joint Conference on Artificial Intelligence 1995;2:1137–1143.
   Google Scholar
• Tadmor T. Does monocyte count have prognostic significance in cancer? Leuk Res 2013; 37: 1193–1194.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–2174.
   PubMed Web of Science ®Google Scholar
• Liu GX, Zhang X, Li S, et al. Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumour Biol 2013; 34: 2741–2746.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2013; 31: 325–331.
   Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte count predicts overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012; 53: 575–580.
   PubMed Web of Science ®Google Scholar
• Bari A, Tadmor T, Sacchi S, et al. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res 2013; 37: 619–623.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502–1509.
   PubMed Web of Science ®Google Scholar
• Von Hohenstaufen KA, Conconi A, de Campos CP, et al. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol 2013; 162: 465–473.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31: 1503–1509.
   PubMed Web of Science ®Google Scholar
• Tsai YD, Wang CP, Chen CY, et al. Pretreatment circulating monocyte count associated with poor prognosis in patients with oral cavity head and neck cancer. Head Neck 2014; 36: 947–953.
   PubMed Web of Science ®Google Scholar
• Sáenz JJ, Izura JJ, Manrique A, et al. Early prognosis in severe sepsis via analyzing the monocyte immunophenotype. Intensive Care Med 2001; 27: 970–977.
   PubMed Web of Science ®Google Scholar
• Young WK, Hyo JK, Chansik P, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. The Oncologist 2012; 17: 871–880.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow KM, Habermann TM, et al. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer J 2013; 3: e110. DOI: 10.1038/bcj.2013.8.
   Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Day 100 peripheral blood absolute lymphocyte/monocyte ratio and survival in classical Hodgkin’s lymphoma postautologous peripheral blood hematopoietic stem cell transplantation. Bone Marrow Res 2013; 2013: 658371.
   PubMedGoogle Scholar
• Romano A, Vetro C, Donnarumma D, et al. Early interim 2-(1) fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to peripheral blood. Haematologica 2012; 97: e21–e23.
   PubMed Web of Science ®Google Scholar